About ELAPRASE (idursulfase)

ELAPRASE is targeted to replace iduronate-2-sulfatase (I2S), the enzyme that is deficient or absent in people with Hunter syndrome.

ELAPRASE is a weekly infusion therapy, which means it’s given intravenously (by IV).

To receive ELAPRASE therapy, you will have to go to a treatment center every week. Typically, the infusion can take up to 3 hours, but there may be additional time for preparation and observation. Patients may require longer infusion times if hypersensitivity reactions occur; however, infusion times should not exceed 8 hours. Your healthcare provider can give you more details about what to expect and can help you plan ahead.

At the treatment center, a healthcare professional will provide therapy and answer any questions you may have. Each infusion center has its own guidelines about what patients are permitted to do while undergoing therapy, and it may be OK to engage in a quiet activity such as reading a book, watching TV, or doing homework. Check with your treatment center before you arrive to find out which activities are acceptable.

As with any new experience, the ELAPRASE infusion might be unfamiliar at first, or the process might even make you nervous. Talk to your doctor about any concerns you have.

> Learn how ELAPRASE helped patients with MPS II in clinical studies